{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T22:39:49Z","timestamp":1790375989703,"version":"4.1.0"},"reference-count":102,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.clml.2018.05.009","type":"journal-article","created":{"date-parts":[[2018,5,23]],"date-time":"2018-05-23T12:55:14Z","timestamp":1527080114000},"page":"508-518.e14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma"],"prefix":"10.1016","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1531-3838","authenticated-orcid":false,"given":"Lorenzo","family":"Falchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Ferrajoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Nava-Parada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2018.05.009_bib2","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1200\/JCO.2016.69.0198","article-title":"Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: the ORCHARRD study","volume":"35","author":"Van Imhoff","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.05.009_bib3","first-page":"7","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clml.2018.05.009_bib4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3109\/02841860903150502","article-title":"A\u00a0systematic review and meta-analysis of immunochemotherapy with rituximab for B-cell non-Hodgkin's lymphoma","volume":"49","author":"Gao","year":"2010","journal-title":"Acta Oncol"},{"key":"10.1016\/j.clml.2018.05.009_bib5","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S0140-6736(12)60605-9","article-title":"Non-Hodgkin lymphoma","volume":"380","author":"Shankland","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2018.05.009_bib6","doi-asserted-by":"crossref","first-page":"e105382","DOI":"10.1371\/journal.pone.0105382","article-title":"Copy number variation analysis on a non-Hodgkin lymphoma case-control study identifies an 11q25 duplication associated with diffuse large B-cell lymphoma","volume":"9","author":"Conde","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2018.05.009_bib10","doi-asserted-by":"crossref","first-page":"4916","DOI":"10.1182\/blood-2007-12-129379","article-title":"Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st century","volume":"111","author":"Brenner","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.009_bib11","first-page":"148","article-title":"Impact of rituximab (Rituxan) on the treatment of B-cell non-Hodgkin's lymphoma","volume":"35","author":"Dotan","year":"2010","journal-title":"P\u00a0T"},{"key":"10.1016\/j.clml.2018.05.009_bib12","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1053\/j.seminhematol.2010.01.011","article-title":"Rituximab: mechanism of action","volume":"47","author":"Weiner","year":"2010","journal-title":"Semin Hematol"},{"key":"10.1016\/j.clml.2018.05.009_bib13","first-page":"676","article-title":"Mechanisms of action of CD20 antibodies","volume":"2","author":"Boross","year":"2012","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.clml.2018.05.009_bib14","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2147\/CMAR.S34273","article-title":"Treatment challenges in the management of relapsed or refractory non-Hodgkin's lymphoma\u2014novel and emerging therapies","volume":"5","author":"Chao","year":"2013","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.clml.2018.05.009_bib15","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.05.009_bib16","doi-asserted-by":"crossref","first-page":"820","DOI":"10.4161\/mabs.29105","article-title":"Rituximab: how approval history is reflected by a corresponding patent filing strategy","volume":"6","author":"Storz","year":"2014","journal-title":"mAbs"},{"key":"10.1016\/j.clml.2018.05.009_bib17","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.009_bib18","first-page":"1927","article-title":"Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study","volume":"92","author":"Coiffier","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.009_bib19","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","article-title":"Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free -survival and response duration compared with the standard weekly x 4 schedule","volume":"103","author":"Ghielmini","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.009_bib20","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1200\/JCO.2005.12.191","article-title":"Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma\u2014a randomized phase II trial of the Minnie Pearl Cancer Research Network","volume":"23","author":"Hainsworth","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.05.009_bib21","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2018.05.009_bib22","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.009_bib23","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","article-title":"Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial","volume":"108","author":"van Oers","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.009_bib24","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","article-title":"Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma","volume":"26","author":"Marcus","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.05.009_bib27","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1200\/JCO.2012.45.0866","article-title":"R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi","volume":"31","author":"Federico","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.05.009_bib28","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.2165\/11201110-000000000-00000","article-title":"Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma","volume":"70","author":"Keating","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.clml.2018.05.009_bib29","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1177\/2040620715622613","article-title":"Obinutuzumab for relapsed or refractory indolent non-Hodgkin's lymphomas","volume":"7","author":"Gabellier","year":"2016","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.clml.2018.05.009_bib30","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.2217\/fon.15.57","article-title":"A\u00a0review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin's lymphomas","volume":"11","author":"Feugier","year":"2015","journal-title":"Future Oncol"},{"key":"10.1016\/j.clml.2018.05.009_bib31","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1200\/JCO.2000.18.17.3135","article-title":"Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment","volume":"18","author":"Davis","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.05.009_bib32","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.3324\/haematol.13440","article-title":"R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL\/TAMO study","volume":"93","author":"Martin","year":"2008","journal-title":"Haematologica"},{"issue":"suppl 4","key":"10.1016\/j.clml.2018.05.009_bib33","doi-asserted-by":"crossref","first-page":"iv31","DOI":"10.1093\/annonc\/mdj996","article-title":"Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study","volume":"17","author":"Hagberg","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2018.05.009_bib34","doi-asserted-by":"crossref","first-page":"3783","DOI":"10.1182\/blood.V112.11.3783.3783","article-title":"The impact of rituximab resistance on overall survival rate in low-grade follicular lymphoma","volume":"112","author":"Abdollahi","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.009_bib35","first-page":"311","article-title":"Novel antibodies in the treatment of non-Hodgkin's lymphoma","volume":"67","author":"Bhat","year":"2009","journal-title":"Neth J Med"},{"key":"10.1016\/j.clml.2018.05.009_bib36","first-page":"1","article-title":"Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab","volume":"8","author":"Smolej","year":"2015","journal-title":"Pharmgenomics Pers Med"},{"key":"10.1016\/j.clml.2018.05.009_bib37","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3324\/haematol.2015.124107","article-title":"Ofatumumab and its role as immunotherapy in chronic lymphocytic leukemia","volume":"100","author":"Sandhu","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.05.009_bib38","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1182\/blood-2007-09-111781","article-title":"Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study","volume":"111","author":"Coiffier","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.009_bib39","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1200\/JCO.2009.25.3187","article-title":"Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia","volume":"28","author":"Wierda","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.05.009_bib40","article-title":"FDA grants full approval to ofatumumab (Arzerra) for CLL","author":"Nelson","year":"2014","journal-title":"Medscape"},{"key":"10.1016\/j.clml.2018.05.009_bib41","author":"Novartis [Internet]"},{"key":"10.1016\/j.clml.2018.05.009_bib42","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.4049\/jimmunol.1000303","article-title":"Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab","volume":"186","author":"Bologna","year":"2011","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.clml.2018.05.009_bib43","first-page":"370","article-title":"Obinutuzumab: A novel anti-CD20 monoclonal antibody for chronic lymphocytic leukemia","volume":"6","author":"Evans","year":"2015","journal-title":"J\u00a0Adv Pract Oncol"},{"key":"10.1016\/j.clml.2018.05.009_bib45","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2018.05.009_bib48","author":"Roche [Internet]"},{"key":"10.1016\/j.clml.2018.05.009_bib49","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1177\/1078155215603230","article-title":"Randomized controlled trials in relapsed\/refractory follicular lymphoma: a systematic review and meta-analysis","volume":"22","author":"Police","year":"2016","journal-title":"J\u00a0Oncol Pharm Pract"},{"key":"10.1016\/j.clml.2018.05.009_bib50","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/1756-8722-5-64","article-title":"Novel CD20 monoclonal antibodies for lymphoma therapy","volume":"5","author":"Cang","year":"2012","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.clml.2018.05.009_bib51","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/2046-4053-1-10","article-title":"Evidence summaries: the evolution of a rapid review approach","volume":"1","author":"Khangura","year":"2012","journal-title":"Syst Rev"},{"key":"10.1016\/j.clml.2018.05.009_bib52","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/s12185-015-1767-3","article-title":"A\u00a0phase II study of bendamustine plus rituximab in Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma previously treated with rituximab: BRB study","volume":"101","author":"Matsumoto","year":"2015","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2018.05.009_bib53","doi-asserted-by":"crossref","first-page":"4299","DOI":"10.1002\/cncr.25280","volume":"116","author":"Morschhauser","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2018.05.009_bib54","article-title":"Response-adapted treatment with rituximab\/bendamustine\/mitoxantrone\/dexamethasone and maintenance therapy with rituximab in patients with follicular lymphoma in relapse or refractory to first-line treatment with immunochemotherapy. RBMDGELTAMO08 trial","volume":"128","author":"Parraga","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.009_bib55","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","article-title":"Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma","volume":"23","author":"Rummel","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.05.009_bib56","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1182\/blood.V128.22.617.617","article-title":"Phase 2 study of venetoclax plus rituximab or randomized ven plus bendamustine+rituximab (BR) versus BR in patients with relapsed\/refractory follicular lymphoma: interim data","volume":"128","author":"Zinzani","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.009_bib57","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990","article-title":"National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment","volume":"87","author":"Cheson","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.009_bib58","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.009_bib59","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.05.009_bib60","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.05.009_bib61","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.05.009_bib62","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-009252","article-title":"Is there a relationship between surgical case volume and mortality in congenital heart disease services? A rapid evidence review","volume":"5","author":"Preston","year":"2015","journal-title":"BMJ Open"},{"key":"10.1016\/j.clml.2018.05.009_bib63","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1182\/blood.V120.21.2744.2744","article-title":"2744 Rituximab in combination with bendamustine or chlorambucil for treating patients with chronic lymphocytic leukemia: interim results of a phase IIIb study (MaBLe) [abstract]","volume":"120","author":"Leblond","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.009_bib64","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.LBA-5.LBA-5","article-title":"Idelalisib plus bendamustine and rituximab (BR) is superior to BR alone in patients with relapsed\/refractory chronic lymphocytic leukemia: results of a phase 3 randomized double-blind placebo-controlled study [abstract]","volume":"126","author":"Zelenetz","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.009_bib65","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/bjh.13061","volume":"167","author":"Awan","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.05.009_bib66","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S1470-2045(15)00465-9","article-title":"Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study","volume":"17","author":"Chanan-Khan","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2018.05.009_bib67","first-page":"150","article-title":"Ibrutinib plus bendamustine and rituximab in previously treated chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL): 2-year follow-up including MRD from the HELIOS study (abstract S430)","volume":"101","author":"Fraser","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.05.009_bib68","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2018.05.009_bib69","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.1016\/S2352-3026(17)30019-4","article-title":"Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial","volume":"4","author":"Jones","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2018.05.009_bib70","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1182\/blood.V128.22.192.192","article-title":"Outcome of patients with complex karyotype in a phase 3 randomized study of idelalisib plus rituximab for relapsed chronic lymphocytic leukemia","volume":"128","author":"Kreuzer","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.009_bib71","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1200\/JCO.2009.26.4556","article-title":"Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia","volume":"28","author":"Robak","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.05.009_bib72","unstructured":"Robak T, Grosicki S, Warzocha K, et\u00a0al. Ofatumumab (O) in combination with fludarabine (F) and cyclophosphamide (C) (OFC) vs. FC in patients with relapsed chronic lymphocytic leukaemia (CLL): results of the phase III study COMPLEMENT 2 [abstract LB219]. Presented at the 20th Congress of the European Hematology Association (EHA) 2015; Vienna, Austria; June 11-14,\u00a02015."},{"key":"10.1016\/j.clml.2018.05.009_bib73","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1080\/10428194.2016.1233536","article-title":"Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial","volume":"58","author":"Robak","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2018.05.009_bib74","first-page":"51","article-title":"Impact of adding rituximab to venetoclax on the rate, quality, and duration of response in patients with relapsed\/refractory chronic lymphocytic leukaemia: a cross-study multivariable analysis","volume":"101","author":"Roberts","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.05.009_bib75","first-page":"10","article-title":"Idelalisib plus bendamustine and rituximab (BR) is superior to BR alone in patients with relapsed\/refractory chronic lymphocytic leukemia: results of a phase 3 randomized double-blind placebo-controlled study","volume":"173","author":"Zelenetz","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.05.009_bib76","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1470-2045(16)30671-4","article-title":"Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial","volume":"18","author":"Zelenetz","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2018.05.009_bib77","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"Forstpointner","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.009_bib78","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1023\/A:1008395214584","article-title":"Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy","volume":"12","author":"Czuczman","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2018.05.009_bib79","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1182\/blood.V126.23.3978.3978","article-title":"Analysis of minimal residual disease in follicular lymphoma patients in GADOLIN, a phase III study of obinutuzumab plus bendamustine versus bendamustine in relapsed\/refractory indolent non-Hodgkin lymphoma [abstract]","volume":"126","author":"Pott","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.009_bib80","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S1470-2045(16)30097-3","article-title":"Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial","volume":"17","author":"Sehn","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2018.05.009_bib81","first-page":"155","article-title":"Obinutuzumab plus bendamustine versus bendamustine alone in patients with rituximab-refractory follicular lymphoma: results from the GADOLIN study","volume":"101","author":"Trneny","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.05.009_bib82","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(15)00447-7","article-title":"Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial","volume":"17","author":"Rummel","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2018.05.009_bib83","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3816\/CLML.2010.n.017","article-title":"ESHAP versus rituximab-ESHAP in frail patients with refractory diffuse large B-cell lymphoma","volume":"10","author":"Aviles","year":"2010","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2018.05.009_bib84","doi-asserted-by":"crossref","first-page":"4814","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.05.009_bib85","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1182\/blood.V128.22.4198.4198","article-title":"Phase I study combining ibrutinib with rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) in patients with relapsed or primary refractory diffuse large B-cell lymphoma (DLBCL): NCI-Cancer Therapeutics Evaluation Program (CTEP) #9588","volume":"128","author":"Sauter","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.009_bib86","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1182\/blood-2010-08-304683","article-title":"Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL","volume":"117","author":"Badoux","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.009_bib87","first-page":"58","article-title":"Durable treatment-free remission and effective retreatment in patients with relapsed\/refractory chronic lymphocytic leukemia who achieved a deep response with venetoclax combined with rituximab","volume":"101","author":"Brander","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.05.009_bib88","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1470-2045(14)70335-3","article-title":"Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study","volume":"15","author":"Burger","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2018.05.009_bib89","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1200\/JCO.2010.33.8061","article-title":"Bendamustine combined with rituximab in patients with relapsed and\/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group","volume":"29","author":"Fischer","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.05.009_bib90","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/j.1365-2141.2010.08317.x","article-title":"A\u00a0randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia","volume":"152","author":"Hillmen","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.05.009_bib91","first-page":"728","article-title":"Efficacy of ibrutinib-based therapy in the treatment of recurrent and refractory forms of chronic lymphocytic leukemia","volume":"101","author":"Kuvshinov","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.05.009_bib92","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1182\/blood-2002-03-0972","article-title":"Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia","volume":"100","author":"Schulz","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.009_bib93","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1200\/JCO.2005.12.516","article-title":"Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia","volume":"23","author":"Wierda","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.05.009_bib94","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1002\/cncr.21882","article-title":"Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma","volume":"106","author":"Tam","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2018.05.009_bib95","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.3109\/10428194.2015.1007504","volume":"56","author":"Fayad","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2018.05.009_bib96","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1182\/blood-2003-11-3911","article-title":"Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma","volume":"103","author":"Kewalramani","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.009_bib97","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1200\/JCO.2012.46.5203","article-title":"Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma","volume":"31","author":"Ohmachi","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.05.009_bib98","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1182\/blood.V116.21.993.993","article-title":"Prognostic impact of germinal center (GC)\/activated B-cell (ABC) classification analysed by immunochemistry, FISH analysis and GEP, in relapsed\/refractory diffuse large B-cell lymphoma (DLBCL): the Bio-CORAL study [abstract]","volume":"116","author":"Thieblemont","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.009_bib99","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s00277-013-1879-x","article-title":"Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma","volume":"93","author":"Vacirca","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2018.05.009_bib100","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1200\/JCO.2005.02.172","article-title":"Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma","volume":"23","author":"Czuczman","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.05.009_bib101","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/leu.2013.334","article-title":"Bendamustine in combination with ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA multicenter phase II trial","volume":"28","author":"Cortelezzi","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.05.009_bib102","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/ajh.23964","article-title":"Ofatumumab added to dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia: results from a phase II study","volume":"90","author":"Doubek","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2018.05.009_bib103","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/ajh.24430","article-title":"A\u00a0phase 2, multicenter study investigating ofatumumab and bendamustine combination in patients with untreated or relapsed CLL","volume":"91","author":"Flinn","year":"2016","journal-title":"Am J Hematol"},{"issue":"suppl","key":"10.1016\/j.clml.2018.05.009_bib104","article-title":"Results of a phase III randomized, controlled study evaluating the efficacy and safety of idelalisib (IDELA) in combination with ofatumumab (OFA) for previously treated chronic lymphocytic leukemia (CLL) [abstract]","volume":"33","author":"Jones","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.05.009_bib105","doi-asserted-by":"crossref","first-page":"915","DOI":"10.3109\/10428194.2014.933217","article-title":"Ofatumumab and bendamustine in previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma","volume":"56","author":"Ujjani","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2018.05.009_bib106","doi-asserted-by":"crossref","first-page":"5645","DOI":"10.1182\/blood.V124.21.5465.5465","article-title":"A\u00a0multi-center, non-randomized phase 2 study of ofatumumab in combination with ICE-chemotherapy (O-ICE) in patients with relapsed\/refractory diffuse large B-cell lymphoma (DLBCL) [abstract]","volume":"124","author":"Tang","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.009_bib107","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1182\/blood.V128.22.2051.2051","article-title":"A\u00a0phase Ib\/II study of combined obinutuzumab (Gazyva) and high-dose methylprednisolone (HDMP) as treatment for patients with chronic lymphocytic leukemia (CLL)","volume":"128","author":"Castro","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.009_bib108","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1182\/blood.V128.22.639.639","article-title":"Phase 1b results of a phase 1b\/2 study of obinutuzmab, ibrutinib, and venetoclax in relapsed\/refractory chronic lymphocytic leukemia (CLL)","volume":"128","author":"Jones","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.009_bib109","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.1182\/blood.V126.23.4151.4151","article-title":"CLL2-BIG-a novel treatment regimen of bendamustine followed by GA101 and ibrutinib followed by ibrutinib and GA101 maintenance in patients with chronic lymphocytic leukemia (CLL): results of a phase II-trial","volume":"126","author":"Von Tresckow","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.009_bib110","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1182\/blood-2013-01-481341","article-title":"Obinutuzumab (GA101) plus CHOP or FC in relapsed\/refractory follicular lymphoma: results of the GAUDI study (BO21000)","volume":"122","author":"Radford","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.009_bib111","doi-asserted-by":"crossref","first-page":"5599","DOI":"10.1182\/blood.V128.22.5599.5599","article-title":"Ibrutinib-based therapy in the treatment of relapsed and refractory chronic lymphocytic leukemia","volume":"128","author":"Kuvshinov","year":"2016","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018300156?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018300156?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:30:32Z","timestamp":1761870632000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265018300156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":102,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S2152265018300156"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2018.05.009","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2018.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}